These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 16267790)

  • 1. Recombinant generation of two fragments of the rat complement inhibitory factor H [FH(SCR1-7) and FH(SCR1-4)] and their structural and functional characterization in comparison to FH isolated from rat serum.
    Demberg T; Heine I; Götze O; Altermann WW; Seliger B; Schlaf G
    Histol Histopathol; 2006 Jan; 21(1):93-102. PubMed ID: 16267790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The partly folded back solution structure arrangement of the 30 SCR domains in human complement receptor type 1 (CR1) permits access to its C3b and C4b ligands.
    Furtado PB; Huang CY; Ihyembe D; Hammond RA; Marsh HC; Perkins SJ
    J Mol Biol; 2008 Jan; 375(1):102-18. PubMed ID: 18028942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rat complement factor H: molecular cloning, sequencing and quantification with a newly established ELISA.
    Demberg T; Pollok-Kopp B; Gerke D; Götze O; Schlaf G
    Scand J Immunol; 2002 Aug; 56(2):149-60. PubMed ID: 12121434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Each of the three binding sites on complement factor H interacts with a distinct site on C3b.
    Jokiranta TS; Hellwage J; Koistinen V; Zipfel PF; Meri S
    J Biol Chem; 2000 Sep; 275(36):27657-62. PubMed ID: 10837479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Staphylococcal Ecb protein and host complement regulator factor H enhance functions of each other in bacterial immune evasion.
    Amdahl H; Jongerius I; Meri T; Pasanen T; Hyvärinen S; Haapasalo K; van Strijp JA; Rooijakkers SH; Jokiranta TS
    J Immunol; 2013 Aug; 191(4):1775-84. PubMed ID: 23863906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of complement-mediated lysis by a peptide derived from SCR 13 of complement factor H.
    Stoiber H; Ammann C; Spruth M; Müllauer B; Eberhart A; Harris CL; Huber CG; Longhi R; Falkensammer B; Würzner R; Dierich MP
    Immunobiology; 2001 May; 203(4):670-86. PubMed ID: 11402501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physiologic inactivation of fluid phase C3b: isolation and structural analysis of C3c, C3d,g (alpha 2D), and C3g.
    Davis AE; Harrison RA; Lachmann PJ
    J Immunol; 1984 Apr; 132(4):1960-6. PubMed ID: 6607952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C5a anaphylatoxin as a product of complement activation up-regulates the complement inhibitory factor H in rat Kupffer cells.
    Schlaf G; Nitzki F; Heine I; Hardeland R; Schieferdecker HL; Götze O
    Eur J Immunol; 2004 Nov; 34(11):3257-66. PubMed ID: 15376195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human factor H-related protein 5 has cofactor activity, inhibits C3 convertase activity, binds heparin and C-reactive protein, and associates with lipoprotein.
    McRae JL; Duthy TG; Griggs KM; Ormsby RJ; Cowan PJ; Cromer BA; McKinstry WJ; Parker MW; Murphy BF; Gordon DL
    J Immunol; 2005 May; 174(10):6250-6. PubMed ID: 15879123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression and regulation of complement factors H and I in rat and human cells: some critical notes.
    Schlaf G; Demberg T; Beisel N; Schieferdecker HL; Götze O
    Mol Immunol; 2001 Aug; 38(2-3):231-9. PubMed ID: 11532284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The human complement regulator factor H binds pneumococcal surface protein PspC via short consensus repeats 13 to 15.
    Duthy TG; Ormsby RJ; Giannakis E; Ogunniyi AD; Stroeher UH; Paton JC; Gordon DL
    Infect Immun; 2002 Oct; 70(10):5604-11. PubMed ID: 12228288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A soluble deletion mutant of the human complement receptor type 1, which lacks the C4b binding site, is a selective inhibitor of the alternative complement pathway.
    Scesney SM; Makrides SC; Gosselin ML; Ford PJ; Andrews BM; Hayman EG; Marsh HC
    Eur J Immunol; 1996 Aug; 26(8):1729-35. PubMed ID: 8765013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rational engineering of a minimized immune inhibitor with unique triple-targeting properties.
    Schmidt CQ; Bai H; Lin Z; Risitano AM; Barlow PN; Ricklin D; Lambris JD
    J Immunol; 2013 Jun; 190(11):5712-21. PubMed ID: 23616575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Analysis of Novel Complement-Targeted Inhibitors, MiniFH, and the Natural Regulators Factor H and Factor H-like Protein 1 Reveal Functional Determinants of Complement Regulation.
    Harder MJ; Anliker M; Höchsmann B; Simmet T; Huber-Lang M; Schrezenmeier H; Ricklin D; Lambris JD; Barlow PN; Schmidt CQ
    J Immunol; 2016 Jan; 196(2):866-76. PubMed ID: 26643478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The catalytically active serine protease domain of human complement factor I.
    Tsiftsoglou SA; Willis AC; Li P; Chen X; Mitchell DA; Rao Z; Sim RB
    Biochemistry; 2005 Apr; 44(16):6239-49. PubMed ID: 15835912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of complement activation by C-reactive protein: targeting the complement inhibitory activity of factor H by an interaction with short consensus repeat domains 7 and 8-11.
    Jarva H; Jokiranta TS; Hellwage J; Zipfel PF; Meri S
    J Immunol; 1999 Oct; 163(7):3957-62. PubMed ID: 10490997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of surface recognition and C3b binding properties of mouse and human complement factor H.
    Cheng ZZ; Hellwage J; Seeberger H; Zipfel PF; Meri S; Jokiranta TS
    Mol Immunol; 2006 Mar; 43(7):972-9. PubMed ID: 16023208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of C3dg binding to a recess formed between short consensus repeats 1 and 2 of complement receptor type 2 (CR2; CD21).
    Prodinger WM; Schwendinger MG; Schoch J; Köchle M; Larcher C; Dierich MP
    J Immunol; 1998 Nov; 161(9):4604-10. PubMed ID: 9794388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An engineered construct combining complement regulatory and surface-recognition domains represents a minimal-size functional factor H.
    Hebecker M; Alba-Domínguez M; Roumenina LT; Reuter S; Hyvärinen S; Dragon-Durey MA; Jokiranta TS; Sánchez-Corral P; Józsi M
    J Immunol; 2013 Jul; 191(2):912-21. PubMed ID: 23772024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The regulatory SCR-1/5 and cell surface-binding SCR-16/20 fragments of factor H reveal partially folded-back solution structures and different self-associative properties.
    Okemefuna AI; Gilbert HE; Griggs KM; Ormsby RJ; Gordon DL; Perkins SJ
    J Mol Biol; 2008 Jan; 375(1):80-101. PubMed ID: 18005991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.